 |
| Photo: Depositphotos.com |
Bain Capital Private Equity has agreed to acquire DSM
Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics,
next-generation statins and anti-fungals.
DSP is a 50/50 joint venture of
Heerlen-based DSM and Sinochem of Beijing. DSM said it was paid about €250m for
its stake in the group.
In 2017, DSP generated sales of approximately €440m. It
has manufacturing sites and sales offices in China, India, the Netherlands,
Spain, the US and Mexico, with approximately 2,000 employees.
‘DSM and Sinochem
have been great supporters of our vision to be the global leader in generic
pharmaceuticals,’ said Karl Rotthier, who heads DSP. ‘Bain Capital is now the
ideal partner to drive DSP into its next stage of global development, given its
deep healthcare expertise and operational skills across its worldwide team,’ he
said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.